Latest Hotspot

Abbisko Therapeutics' CSF-1R Inhibitor, Pimicotinib, Approved for Global Multicenter Phase 3 Clinical Trials in Europe

13 September 2023
3 min read

On September 11, 2023, Abbisko Therapeutics announced that its innovative CSF-1R inhibitor pimicotinib (ABSK021) was approved by the European Medicines Agency (EMA) to enter a randomized, double-blind, placebo-controlled, multi-center phase III clinical trial. The study primarily evaluates the drug's effectiveness and safety for patients with tenosynovial giant cell tumor (TGCT). 

Pimicotinib is a novel oral, highly selective, highly active small molecule CSF-1R inhibitor developed by Abbisko Therapeutics. Research has shown that blocking the CSF1/CSF-1R signaling pathway can regulate and alter macrophage functions, playing a role in various macrophage-related diseases. Previously, pimicotinib was included in the breakthrough treatment varieties by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration and granted the Breakthrough Therapy Designation by the US FDA. On June 8, 2023, pimicotinib (ABSK021) was granted the PRIME designation by the European EMA for the treatment of inoperable TGCT patients.

The global multi-center phase III clinical study of pimicotinib has been initiated in China and the United States simultaneously and plans to start patient enrolment in Europe soon as well. The results of the study will be used for NDA applications in the Chinese, U.S., and European markets.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

The clinical phase 1b trial results of Pimicotinib for the treatment of tenosynovial giant cell tumors were presented at the 2023 American Society of Clinical Oncology (ASCO) meeting. In the study, the candidate drug demonstrated good efficacy and safety. According to the assessment by the Independent Review Committee (IRC) based on RECIST1.1, the objective remission rate of the group receiving a dosage of 50mg once daily reached 77.4%, and no significant hepatic toxicity was observed. 89.8% of patients continue to receive treatment. Joint mobility, pain, and stiffness all showed a trend of alleviation after treatment with Pimicotinib.

CSF-1R is the receptor for the cytokine CSF-1, and is also an important member of the receptor tyrosine kinases, which are closely correlated with the occurrence and development of inflammation. In the tumor microenvironment (TME), the signal of CSF-1R and its ligand CSF-1 can induce the differentiation and survival of tumor-associated macrophages (TAMs), thereby promoting the growth of tumor cells.

图形用户界面, 应用程序, Teams

描述已自动生成

According to the information disclosed by the Synapse Database, as of September 12, 2023, there were a total of 60 drugs under development targeting CSF-1R, covering 106 indications, with 99 institutions engaged in research, involving 1134 related clinical trials, and as many as 7825 patents. 

The CSF-1R target has excellent therapeutic potential in anti-tumor treatment, and it is hoped that more such new drugs will be approved for marketing to benefit patients.

图形用户界面, 文本, 应用程序

描述已自动生成

Ways to Evaluate the Worldwide R&D Progress of Our Study Sequence
Bio Sequence
2 min read
Ways to Evaluate the Worldwide R&D Progress of Our Study Sequence
13 September 2023
The progress of R&D efforts in a life-science area of study can greatly affect the likelihood of breakthroughs and advancements. So, how do we analyze the global research and development progress of the sequence we are studying? I recommend that you use the Patsnap Bio Sequence Database to query data and information.
Read →
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
Latest Hotspot
3 min read
Phanes Therapeutics reports its first patient has been administered with PT217 in a Phase 1 trial
13 September 2023
Biotech firm, Phanes Therapeutics, has announced its Phase 1 clinical trial of PT217, a first-in-class drug targeting DLL3 and CD47 in small cell lung cancer. The trial uses a new IgG-like bispecific antibody and the first patient has been treated.
Read →
Searching for Modified Sequences: The Best Biological Databases to Consider
Bio Sequence
2 min read
Searching for Modified Sequences: The Best Biological Databases to Consider
13 September 2023
Sequence modification is an important attribute of a sequence, particularly in the field of small nucleic acids. Sequence modifications, including fluorescence labeling, glycosylation, phosphorylation, and others, can enhance the functionality of a sequence, making them highly meaningful. In the Patsnap Bio Sequence Database, you can search for modified sequences.
Read →
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
Latest Hotspot
4 min read
Seladelpar from CymaBay Reaches Significant Statistical Levels for primary and key Secondary endpoints in the RESPONSE Phase 3 Trial
13 September 2023
Biotech firm CymaBay Therapeutics, Inc. revealed positive Phase 3 trial outcomes for seladelpar, a novel treatment for liver and chronic diseases, including primary biliary cholangitis. Meeting all primary and key secondary endpoints.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.